Immutep Receives FDA Fast Track designation for NSCLC treatment
Immutep (IMM) receives US FDA Fast Track designation for its efti drug candidate as a...
Immutep Shares positive data from phase 2b AIPAC trial
Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase...
Immutep Completes Phase II recruitment
Immutep (IMM) completes recruitment for its phase II study for non-small cell lung cancer
The last patient has now...
Immutep Receives $3.4 million R&D tax incentive
Immutep (IMM) is granted a $3.4 million research and development tax incentive from the French Government
The...
Biotech company Immutep (IMM) has tapped institutional investors for a neat $29.6 million to fund its cancer and autoimmune diseases treatment trials
The...
